Josephine (69 years old)

Josephine, 69 years old, currently receives treatment with trastuzumab deruxtecan in second line for HR- HER2+ MBC.

Assessment summary

• Postmenopausal
• No relevant comorbidities
• ECOG PS: 1
• Medical history:
  • ~2 years ago: diagnosis de novo HR- HER2+ MBC
  • Tumour biology (liver lesion): invasive ductal carcinoma, ER 0%, PgR 0%, HER2 IHC 3+
  • First-line treatment for bone, liver and lung metastases:
    • Paclitaxel + trastuzumab-pertuzumab for 10 months
  • Second-line treatment for liver and brain progression:
    • SRS for the 3 brain metastases
    • Trastuzumab deruxtecan for 14 months without toxicity
• PET-CT at 14 months of trastuzumab deruxtecan treatment: new liver lesions
• Brain MRI: partial response of brain metastases that were previously treated